The new drug application (NDA) is supported by results from a two-year, double-blind, placebo-controlled, randomized Phase III clinical trial of 1,382 men with advanced prostate cancer on androgen deprivation therapy.
GTx expects to hear within several weeks whether the NDA will receive priority or standard review.